☆ 4.3 Review

Vaccination as a Triggering Event for Autoimmune Hepatitis

SEMINARS IN LIVER DISEASE (2009)

期刊

SEMINARS IN LIVER DISEASE

卷 29, 期 3, 页码 331-334

出版社

THIEME MEDICAL PUBL INC

DOI: 10.1055/s-0029-1233537

关键词

Autoimmune hepatitis; vaccination; yellow fever; hepatitis A

类别

Gastroenterology & Hepatology

向作者/读者索取更多资源

Protocol

Reagent

摘要

The pathogenesis of autoimmune hepatitis entails complex interactions between triggering factors, autoantigens, genetic predisposition, and immunoregulatory networks. Implicated triggering factors are numerous and Include toxins, medications, and infectious agents. In this article, we present a unique case of a 31-year-old woman with severe autoimmune hepatitis apparently abruptly triggered by vaccination. All evidence suggests this was an idiosyncratic response to either hepatitis A or yellow fever vaccination.

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Review Immunology

What Constitutes Protective Immunity Following Yellow Fever Vaccination?

Jolynne Mokaya, Derick Kimathi, Teresa Lambe, George M. Warimwe

Summary: Yellow fever remains a global health threat, with efforts to eliminate it by vaccinating one billion people at risk by 2026. The current vaccine provides good protection, but production challenges limit its use, leading to exploration of alternative dosing strategies. Understanding immune responses to vaccination and exploring antibody characteristics and cell-mediated immunity are important for developing a comprehensive understanding of protective immunity.

VACCINES (2021)

添加到收藏夹

Article Immunology

Potential autoimmune encephalitis following yellow fever vaccination: A report of three cases

Bruno Fukelmann Guedes, Ana Freitas Ribeiro, Lecio Figueira Pinto, Jose Ernesto Vidal, Fernanda Gurgel de Oliveira, Jaques Sztajnbok, Augusto Cesar Penalva de Oliveira, Mateus Mistieri Simabukuro

Summary: Meningoencephalitis following yellow fever vaccination can lead to autoimmune encephalitis syndromes, with antibodies like Anti-N-methyl-D-aspartate-r being identified. Proper diagnosis and treatment are crucial in these cases.

JOURNAL OF NEUROIMMUNOLOGY (2021)

添加到收藏夹

Review Immunology

Autoimmune hepatitis after COVID-19 vaccination

Han Zheng, Ting Zhang, Yiyao Xu, Xin Lu, Xinting Sang

Summary: Cases of autoimmune hepatitis (AIH) after COVID-19 vaccination have been reported, suggesting a potential autoimmune reaction. This study summarizes 27 cases of AIH, providing emerging evidence of such autoimmune phenomena in response to COVID-19 vaccines. Factors such as molecular mimicry, adjuvants, epitope spreading, and bystander activation may contribute to the development of AIH. Corticosteroids appear to be effective in treating post-vaccination AIH, but further research is needed to determine the exact mechanism and causality.

FRONTIERS IN IMMUNOLOGY (2022)

添加到收藏夹

Article Pharmacology & Pharmacy

COVID-19 vaccination-related autoimmune hepatitis-a perspective

Consolato M. Sergi

Summary: Autoimmune hepatitis (AIH) is liver inflammation characterized by autoimmunity to hepatocytes. mRNA vaccines have been useful in tackling the COVID-19 pandemic but have been associated with side effects such as myocarditis and AIH. A comparison between titin protein and myocarditis suggests the relevance of autoimmune phenomena following mRNA technology-based vaccination. The co-existence of myasthenia gravis and AIH and the presence of anti-titin antibodies highlight the potential for autoimmune reactions. Balancing the pros and cons of booster shots is crucial.

FRONTIERS IN PHARMACOLOGY (2023)

添加到收藏夹

Article Public, Environmental & Occupational Health

New recommendation on yellow fever booster vaccination in Germany

Frieder Schaumburg, Franziska Schuler, Martin P. Grobusch

Summary: The Permanent Vaccination Commission in Germany has updated its recommendations for yellow fever vaccination, conflicting with WHO recommendations. The article presents arguments supporting adherence to the WHO recommendations, including the complexity of booster vaccinations and the importance of T-cell driven immune response.

TRAVEL MEDICINE AND INFECTIOUS DISEASE (2022)

添加到收藏夹

Article Immunology

Autoimmune hepatitis triggered by SARS-CoV-2 vaccination

Elise Vuille-Lessard, Matteo Montani, Jaume Bosch, Nasser Semmo

Summary: Autoimmune diseases have been reported to develop after SARS-CoV-2 infection, as well as following vaccination against the virus. The potential mechanisms involve molecular mimicry and bystander activation. Further investigation is needed to understand the link between SARS-CoV2 vaccination and autoimmune diseases.

JOURNAL OF AUTOIMMUNITY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis

Tobias Boettler, Benedikt Csernalabics, Henrike Salie, Hendrik Luxenburger, Lara Wischer, Elahe Salimi Alizei, Katharina Zoldan, Laurenz Krimmel, Peter Bronsert, Marius Schwabenland, Marco Prinz, Carolin Mogler, Christoph Neumann-Haefelin, Robert Thimme, Maike Hofmann, Bertram Bengsch

Summary: This case report highlights the occurrence of autoimmune hepatitis episodes following COVID-19 vaccination in a patient with distinctive T cell-dominant immune-mediated hepatitis. Liver tissue analysis revealed an immune infiltrate with activated cytotoxic CD8 T cells predominantly distributed, indicating a unique pathomechanism associated with vaccination-induced antigens.

JOURNAL OF HEPATOLOGY (2022)

添加到收藏夹

Review Immunology

Duration of Protection After Vaccination Against Yellow Fever-Systematic Review and Meta-analysis

Kerstin Kling, Cristina Domingo, Christian Bogdan, Steven Duffy, Thomas Harder, Jeremy Howick, Jos Kleijnen, Kevin McDermott, Ole Wichmann, Annelies Wilder-Smith, Robert Wolff

Summary: The duration of protection after a single dose of yellow fever vaccine is a topic of debate. A systematic literature review and meta-analysis revealed that the seroprotection rates after single vaccination dose were close to 100% within 3 months and remained high in adults for 5 to 10 years. However, the seroprotection rate for children vaccinated before age 2 years was 52% within 5 years after primary vaccination. Immunodeficient persons showed relevant waning of seroprotection. The extent of waning depends on age and immune status at primary vaccination.

CLINICAL INFECTIOUS DISEASES (2022)

添加到收藏夹

Article Immunology

Durability of neutralizing antibodies against yellow fever virus after vaccination in healthy adults

Riccardo De Santis, Giovanni Faggioni, Alessandra Amoroso, Andrea Ciammaruconi, Alice Pomponi, Maria Stella Lia, Donatella Amatore, Filippo Molinari, Giancarlo Petralito, Paola Stefanelli, Giovanni Rezza, Florigio Lista

Summary: According to the World Health Organization, one dose of yellow fever vaccine can provide lifelong protection in healthy adults. However, there is limited information available regarding the long-term persistence of neutralizing antibodies. Our study evaluated the persistence of neutralizing antibodies in a large group of military personnel who were vaccinated up to 47 years ago. The results showed that 99.1% of the participants had detectable neutralizing antibodies, with the highest levels observed in those vaccinated within 1 year. These findings confirm that neutralizing antibodies can persist for up to 47 years after a single dose of yellow fever vaccine.

VACCINE (2023)

添加到收藏夹

Article Immunology

Characterization and Investigation of Risk Factors for Late-Relapsing Hepatitis After Yellow Fever

Izabela Mauricio de Rezende, Max A. McClure, Leonardo S. Pereira, Jordana R. B. Fradico, Adriana R. C. Cenachi, Alexandre S. Moura, Luisa L. de A. Paladino, Maria Rita T. Dutra, Pedro A. Alves, Marcelo A. P. Xavier, Rodrigo F. do C. Said, Dario B. Ramalho, Thaysa D. P. Gama, Olindo A. Martins-Filho, Thomas P. Monath, Andrea Teixeira-Carvalho, Betania P. Drumond, Angelle D. LaBeaud

Summary: Late-relapsing hepatitis after yellow fever presents with nonspecific symptoms around 60 days after the acute phase, but has a benign outcome.

CLINICAL INFECTIOUS DISEASES (2023)

添加到收藏夹

Article Clinical Neurology

Multiple sclerosis: Is there a risk of worsening after yellow fever vaccination?

Caroline Papeix, Julie Mazoyer, Elisabeth Maillart, Caroline Bensa, Anne-Laure Dubessy, Catherine Goujon, Odile Launay, Christine Lebrun-Frenay, Celine Louapre, Serge Mrejen, Valerie Pourcher, Michel Rosenheim, Bruno Stankoff, Jean-Sebastien Vidal, Catherine Lubetzki

Summary: The study conducted on the French national cohort found that the yellow fever vaccine (YFV) does not worsen the course of relapsing-remitting multiple sclerosis (RR-MS).

MULTIPLE SCLEROSIS JOURNAL (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome

Cumali Efe, Anand V. Kulkarni, Benedetta Terziroli Beretta-Piccoli, Bianca Magro, Albert Friedrich Staettermayer, Mustafa Cengiz, Daniel Clayton-Chubb, Craig Lammert, Christine Bernsmeier, Ozlem Gul, Fatima Higuera-de la Tijera, Margarita Anders, Ellina Lytvyak, Mete Akin, Tugrul Purnak, Rodrigo Liberal, Mirta Peralta, Berat Ebik, Serkan Duman, Nurhan Demir, Yasemin Balaban, Alvaro Urzua, Fernando Contreras, Maria Grazia Venturelli, Yilmaz Bilgic, Adriana Medina, Marcos Girala, Fulya Guensar, Maria-Carlota Londono, Theodoros Androutsakos, Ayelen Kisch, Alper Yurci, Fatih Guezelbult, Yasir Furkan Cagin, Enver Avci, Murat Guezelbulut, Emine Kubra Dindar-Demiray, Murat Harputluoglu, Rahul Kumar, Sanjaya K. Satapathy, Manuel Mendizabal, Marcelo Silva, Stefano Fagiuoli, Stuart K. Roberts, Nese Karadag Soylu, Ramazan Idilman, Eric M. Yoshida, Aldo J. Montano-Loza, George N. Dalekos, Ezequiel Ridruejo, Thomas D. Schiano, Staffan Wahlin

Summary: This study evaluated the clinical features, treatment response, and outcomes of liver injury following SARS-CoV-2 vaccination. The liver injury was predominantly hepatocellular and some patients showed features of immune-mediated hepatitis. Corticosteroid therapy may be beneficial for patients with immune-mediated features or severe hepatitis. The overall outcome was generally favorable, but a few patients experienced vaccine-associated liver failure.

HEPATOLOGY (2022)

添加到收藏夹

Review Immunology

Vaccine-Related Autoimmune Hepatitis: Emerging Association with SARS-CoV-2 Vaccination or Coincidence?

Ioannis P. Trontzas, Konstantinos G. Kyriakoulis, Ioannis A. Vathiotis, Alexandros Syrigos, Georgios Kounadis, Sofia Siasiakou, Garyphalia Poulakou

Summary: There is an increasing number of AIH-like cases following SARS-CoV-2 vaccination, with most cases requiring immunosuppressive therapy. Early diagnosis is crucial, especially for patients with pre-existing liver disease.

VACCINES (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Investigating Acute Hepatitis after SARS-CoV-2 Vaccination or Infection: A Genetic Case Series

Elisa Bernasconi, Matteo Biagi, Stefania Di Agostino, Carmela Cursaro, Cristina Felicani, Enrico Ronconi, Elena Franchi, Arianna Carmen Costanzo, Filippo Gabrielli, Alessia Cavicchioli, Giuseppe Ienopoli, Paolo Marenghi, Alessandra Bartoli, Beatrice Serra, Davide Scalabrini, Pamela Sighinolfi, Pietro Andreone

Summary: This study described a case series of patients who developed acute hepatitis following SARS-CoV-2 vaccination or infection, and speculated a possible genetic susceptibility in the pathogenesis.

BIOMEDICINES (2023)

添加到收藏夹

Article Rheumatology

Seroconversion of rheumatoid arthritis patients after yellow fever vaccination

Betina Soares dos Reis, Felipe Cintra Staub, Andrea Koishi, Camila Zanluca, Claudia Nunes Duarte dos Santos, Thelma L. Skare, Barbara Stadler Kahlow

Summary: The study found that fractionated dose of yellow fever vaccine is effective and safe in rheumatoid arthritis patients, with no clinical infection symptoms observed in the patients.

CLINICAL RHEUMATOLOGY (2022)

添加到收藏夹

Article Gastroenterology & Hepatology

Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study

Donghee Kim, Nia Adeniji, Nyann Latt, Sonal Kumar, P. Patricia Bloom, S. Elizabeth Aby, Ponni Perumalswami, Marina Roytman, Michael Li, S. Alexander Vogel, M. Andreea Catana, Kara Wegermann, M. Rotonya Carr, Costica Aloman, L. Vincent Chen, Atoosa Rabiee, Brett Sadowski, Veronica Nguyen, Winston Dunn, D. Kenneth Chavin, Kali Zhou, Blanca Lizaola-Mayo, Akshata Moghe, Jose Debes, Tzu-Hao Lee, D. Andrea Branch, Kathleen Viveiros, Walter Chan, M. David Chascsa, Paul Kwo, Renumathy Dhanasekaran

Summary: The study identified that alcohol-related liver disease, decompensated cirrhosis, and hepatocellular carcinoma are risk factors predicting higher mortality in patients with chronic liver disease and COVID-19, while Hispanic ethnicity and decompensated cirrhosis are associated with severe COVID-19.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study

Thomas Marjot, Andrew M. Moon, Jonathan A. Cook, Sherief Abd-Elsalam, Costica Aloman, Matthew J. Armstrong, Elisa Pose, Erica J. Brenner, Tamsin Cargill, Maria-Andreea Catana, Renumathy Dhanasekaran, Ahad Eshraghian, Ignacio Garcia-Juarez, Upkar S. Gill, Patricia D. Jones, James Kennedy, Aileen Marshall, Charmaine Matthews, George Mells, Carolyn Mercer, Ponni Perumalswami, Emma Avitabile, Xialong Qi, Feng Su, Nneka N. Ufere, Yu Jun Wong, Ming-Hua Zheng, Eleanor Barnes, Alfred S. Barritt, Gwilym J. Webb

Summary: This international registry study demonstrates that patients with cirrhosis are at increased risk of death from COVID-19. Mortality from COVID-19 was particularly high among patients with more advanced cirrhosis and those with alcohol-related liver disease.

JOURNAL OF HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

A Digital Case-Finding Algorithm for Diagnosed but Untreated Hepatitis C: A Tool for Increasing Linkage to Treatment and Cure

Brooke Wyatt, Ponni Perumalswami, Anna Mageras, Mark Miller, Alyson Harty, Ning Ma, Chip A. Bowman, Francina Collado, Jihae Jeon, Lismeiry Paulino, Amreen Dinani, Douglas Dieterich, Li Li, Maxence Vandromme, Andrea D. Branch

Summary: The study developed a DBU phenotyping algorithm that efficiently identified potential HCV treatment candidates and improved treatment completion rates through navigation and coordination. Findings showed that DBU patients who could not be contacted were less likely to receive treatment, with over half of them having significant fibrosis.

HEPATOLOGY (2021)

添加到收藏夹

Article Psychology, Clinical

Facilitating engagement of persons with opioid use disorder in treatment for hepatitis C virus infection via telemedicine: Stories of onsite case managers

Andrew H. Talal, Urmo Jaanimagi, Kathleen Davis, Jordan Bailey, Barbara M. Bauer, Arpan Dharia, Saliyah George, Anthony McLeod, Karen Morton, Ann Nugent, Marija Zeremski, Amreen Dinani, Don C. Des Jarlais, Ponni V. Perumalswami, Jonathan N. Tobin, Suzanne S. Dickerson

Summary: This study focuses on promoting HCV treatment among persons with opioid use disorder through telemedicine and onsite medication. Case managers play a crucial role in establishing trust, identifying competing priorities, and developing personalized care approaches to increase participation.

JOURNAL OF SUBSTANCE ABUSE TREATMENT (2021)

添加到收藏夹

Article Medicine, Research & Experimental

Patient-centered HCV care via telemedicine for individuals on medication for opioid use disorder: Telemedicine for Evaluation, Adherence and Medication for Hepatitis C (TEAM-C)

Andrew H. Talal, Marianthi Markatou, Elisavet M. Sofikitou, Lawrence S. Brown, Ponni Perumalswami, Amreen Dinani, Jonathan N. Tobin

Summary: The TEAM-C project aims to evaluate the effectiveness of telemedicine treatment for HCV among those with opioid use disorder, with the goal of improving access to healthcare resources for hepatitis C patients. Through rigorous study design and implementation, the project has provided a new treatment option for this specific population, demonstrating feasibility and engagement principles through the initial randomized trial of telemedicine targeted at a vulnerable population.

CONTEMPORARY CLINICAL TRIALS (2022)

添加到收藏夹

Article Oncology

Hepatocellular carcinoma surveillance, incidence, and tumor doubling times in patients cured of hepatitis C

Ponni V. Perumalswami, Brooke Wyatt, Chip A. Bowman, Krupa Patel, Anna Mageras, Sara C. Lewis, Andrea D. Branch

Summary: This study finds that HCC surveillance is associated with sociodemographic factors (insurance status and race/ethnicity) among patients cured of HCV. Guideline-concordant surveillance is needed to address healthcare disparities.

CANCER MEDICINE (2022)

添加到收藏夹

Article Substance Abuse

The impact of COVID-19 on trends in alcohol use disorder treatment in Veterans Health Administration

Ponni V. V. Perumalswami, Sidonie Kilpatrick, Madeline C. C. Frost, Megan A. A. Adams, Hyungjin Myra Kim, Lan Zhang, Lewei Lin (Allison)

Summary: This study examined the trends of alcohol use disorder (AUD) treatment in the Veterans Health Administration (VHA) in the United States before and during the COVID-19 pandemic. The results showed that the percentage of VHA patients with an AUD diagnosis receiving AUD treatment declined during COVID-19 mainly due to a decrease in psychotherapy. Despite an increase after the start of COVID-19, the percentage of patients receiving AUD treatment remained lower than the pre-COVID-19 period at the end of the study.

ADDICTION (2023)

添加到收藏夹

Review Gastroenterology & Hepatology

Definition and measurement of alcohol-associated insight in early liver transplantation for acute alcohol-associated hepatitis: A systematic review

Gerald Scott Winder, Erin G. Clifton, Anne C. Fernandez, Mark MacEachern, Sarah Andrews, Ponni Perumalswami, Andrea F. DiMartini, Jessica L. Mellinger

Summary: Alcohol is closely related to liver disease and transplantation. Clinical evaluations and decisions in this area are challenging due to the complexity of psychosocial assessments and interpretation of psychiatric and substance use disorder data. Acute alcohol-associated hepatitis (AAH) patients have unique characteristics such as recent or active substance use, high mortality rate, psychiatric comorbidities, and urgent evaluation and treatment timelines. This systematic review highlights the lack of standardized definition and measurement of alcohol-associated insight (AAI) in the evaluation and decision-making process for AAH patients undergoing early liver transplantation (eLT).

LIVER TRANSPLANTATION (2023)

添加到收藏夹

Article Gastroenterology & Hepatology

Reexamining psychosocial clearance: A procedural framework for psychosocial evaluation in liver transplantation

Gerald Scott Winder, Anne C. Fernandez, Ponni V. Perumalswami, Jessica L. Mellinger, Erin G. Clifton

Summary: Psychosocial and nonmedical phenomena are common in liver transplantation evaluations and pose challenges to clinicians. There is a lack of consensus among clinicians and centers regarding psychosocial policies and practices. This article proposes a framework for psychosocial evaluation procedures, identifies common pitfalls, and suggests practical improvement strategies.

LIVER TRANSPLANTATION (2023)

添加到收藏夹

Meeting Abstract Gastroenterology & Hepatology

BEHAVIORAL HEALTH UTILIZATION PATTERNS BEFORE AND AFTER A NEW DIAGNOSIS OF LIVER DISEASE IN PATIENTS WITH HAZARDOUS ALCOHOL USE: IS THE DIAGNOSIS OF LIVER DISEASE A REACHABLE MOMENT?

Ponni V. Perumalswami, Brittany L. Cornwell, John F. McCarthy, Benjamin R. Szymanski, Ira R. Katz

HEPATOLOGY (2022)

添加到收藏夹

Meeting Abstract Gastroenterology & Hepatology

THE SCAN-ECHO FORCE MULTIPLIER EFFECT BUILDS PRIMARY CARE PROVIDER CAPACITY THROUGH VIRTUAL CONSULTATIONS TO IMPROVE SURVIVAL FOR VETERANS LIVING WITH LIVER DISEASE

Ponni V. Perumalswami, Kyle Kumbier, Bradley Youles, Patrick Belancourt, Sameer Saini, Grace L. Su

HEPATOLOGY (2021)

添加到收藏夹

Meeting Abstract Gastroenterology & Hepatology

AN OPEN ACCESS HEPATITIS C VIRUS CASE CONSULTING PROGRAM TO EXPAND FRONTLINE COMMUNITY PROVIDER CAPACITY

Ponni V. Perumalswami, Robert McMorrow, Kaylyn Curtis, Erin Wright, Audrey Hazelbaker, Mary F. Myrick, Maureen Mead, Lynsie Stepanski, Dan Oliver, Miranda Jackson, Andrea Daoust, Timothy Shewcraft, Allison Lin, Amy Bohnert, Brandon Harkonen, Sheba Sethi, Anna S. Lok

HEPATOLOGY (2021)

添加到收藏夹

Meeting Abstract Gastroenterology & Hepatology

INADEQUATE HEALTH LITERACY IS ASSOCIATED WITH LOWER RATES OF HEPATOCELLULAR CARCINOMA SURVEILLANCE IN PATIENTS WITH CIRRHOSIS

Kerry Lindquist, Elliot B. Tapper, Brooke Wyatt, Amanda Marshall, Pratima Sharma, Alan Wilson, Matoumba M. Claiborne, Marie-Louise Holiday, Andrew W. Tai, Heather McCurdy, Grace L. Su, Ponni V. Perumalswami

HEPATOLOGY (2021)

添加到收藏夹

Meeting Abstract Gastroenterology & Hepatology

PRACTICAL BARRIERS TO TELEHEALTH VISITS IN HEPATOLOGY

Chip Bowman-Zamora, Ponni V. Perumalswami, Lon Kai Pang, Patricia Thai, Kaiyi Jiang, Zhuoran Yao, Shawn Fan, Cynthia Chen, Robert Chen, Sabia Abidi, Gary Woods, Costica Aloman, John R. Treichler, Andrea D. Branch

HEPATOLOGY (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

Innovations in Hepatitis C Screening and Treatment

Arpan A. Patel, Aileen Bui, Eian Prohl, Debika Bhattacharya, Su Wang, Andrea D. Branch, Ponni Perumalswami

Summary: New therapies offer hope for curing millions of people with HCV infection, but achieving global HCV elimination goals remains challenging. The current standard has shifted towards universal HCV screening and treatment, yet there are significant barriers between diagnosis and cure that require innovative care models to address.

HEPATOLOGY COMMUNICATIONS (2021)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.